Description

Clinical Evidence

• Clinical studies on analogs of GHRH with extended half-lives (like CJC-1295) show increased GH and IGF-1 concentrations for up to 6 days post-injection.
• A human study published in The Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006) reported dose-dependent increases in GH and IGF-1, with minimal desensitization over repeated dosing.
• CJC-1295 DAC has been investigated for its potential in age-related hormone decline, metabolic syndromes, and muscle wasting conditions.
Note: CJC-1295 without DAC (also called Mod GRF 1-29) has a much shorter half-life (30 minutes), making CJC-1295 with DAC more suitable for long-term studies.

Potential Side Effects

Most observed effects are mild and based on anecdotal and early clinical findings. These may include:
• Flushing or tingling shortly after injection
• Temporary water retention or mild swelling
• Joint stiffness (linked to GH elevation)
• Increased appetite
• Injection site irritation
• Rare: fatigue or light-headedness
As with all GH-related compounds, prolonged elevation of IGF-1 levels may carry theoretical long-term risks if not appropriately controlled.

Disclaimer

This peptide is intended for research use only and is not approved for human or veterinary use. All statements regarding benefits are based on preclinical and early-phase clinical data. It should only be handled by qualified professionals in a controlled laboratory setting.